Document is current
Any future updates will be listed below
-
Authors
Shah, Nirav N. https://orcid.org/0000-0002-4336-1071
Johnson, Bryon D.
Schneider, Dina
Zhu, Fenlu
Szabo, Aniko https://orcid.org/0000-0002-8129-0614
Keever-Taylor, Carolyn A. https://orcid.org/0000-0002-3085-6876
Krueger, Winfried
Worden, Andrew A.
Kadan, Michael J.
Yim, Sharon https://orcid.org/0000-0001-6442-1320
Cunningham, Ashley
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
Fenske, Timothy S.
Dropulić, Boro https://orcid.org/0000-0002-3861-7677
Orentas, Rimas
Hari, Parameswaran
- License Information
-
More Information
Article History
Received: 16 March 2020
Accepted: 26 August 2020
First Online: 5 October 2020
Competing interests
: N.N.S. reports honoraria, travel support and research funding from Miltenyi Biotec; honoraria from Incyte and Celgene; service on scientific advisory boards for Kite, Celgene, TG Therapeutics and Lily; and institutional research support for clinical trials from BMS and Miltenyi Biotec. D.S. reports employment with Lentigen, a Miltenyi Biotec company. B.D.J. reports travel support and research funding from Miltenyi Biotec. A.S. has no competing financial interest with regard to this submission. F.Z. has no competing financial interests with regard to this submission. C.A.K.-T. has no competing financial interest with regard to this submission. W.K. reports employment with Lentigen, a Miltenyi Biotec company. A.A.W. reports employment with Lentigen, a Miltenyi Biotec company. M.J.K. reports employment with Lentigen, a Miltenyi Biotec company. S.Y. has no competing financial interest with regard to this submission. A.C. has no competing financial interest with regard to this submission. M.H. reports research support funding from Takeda Pharmaceutical Company and Spectrum Pharmaceuticals; consultancy with Incyte Corporation, ADC Therapeutics, Celgene, Pharmacyclics, Omeros and Verastem; and speaker’s bureau with Sanofi Genzyme and AstraZeneca. T.S.F. reports research funding from Millennium, Kyowa, TG Therapeutics, Portola and Curis; consulting honoraria from Genentech, Adaptive Biotechnologies, AbbVie, Verastem, Kite and MorphoSys; and speaking honoraria from Genentech, Sanofi, Seattle Genetics, AstraZeneca, Celgene and Adaptive Biotechnologies. B.D. reports employment with Lentigen, a Miltenyi Biotec company. R.O. reports prior employment and an ongoing consulting relationship with and research support from Lentigen, a Miltenyi Biotec company, and consulting for Umoja Biopharma. P.H. reports honoraria and travel support from Miltenyi Biotec; research grants from BMS, Takeda, Janssen and Bluebird; and honoraria from BMS, Takeda, Amgen, Karyopharm, Janssen, Incyte, Sanofi and GSK.
